SCHEMBL19344256

SCHEMBL19344256

CSc1ncnn2c([C@@H]3O[C@H](CN4CC(F)(F)CC45CCN(CC#N)CC5)[C@H]4OC(C)(C)O[C@H]43)ccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19344261 0.91 PRMT5 (0.31) —
SCHEMBL19343984 0.90 PRMT5 (0.36) —
SCHEMBL19344257 0.90 PRMT5 (0.32) —
SCHEMBL19344260 0.89 PRMT5 (0.30) —
SCHEMBL19344263 0.89 PRMT5 (0.31) —
SCHEMBL19344511 0.88 PRMT5 (0.30) —
SCHEMBL19344255 0.87 OPRM1 (0.32) —
SCHEMBL22434992 0.81 PRMT5 (0.37) —
SCHEMBL23584751 0.80 — —
SCHEMBL22434945 0.79 PRMT5 (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed
WO-2017153186-A1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-14 — — WO disclosed
Send feedback